Publications

Kestrel and Kite: 52-Week Results From Two Phase Iii Pivotal Trials of Brolucizumab for Diabetic Macular Edema

AuthID
P-00W-DC8

Author(s)

Brown, D

Emanuelli, A

Bandello, F

Barranco, JJE

Figueira, J

Souied, E

Wolf, S

Gupta, V

Ngah, NF

Liew, G

Tuli, R

Tadayoni, R

Dhoot, D

Wang, LX

Bouillaud, E

Wang, Y

Kovacic, L

Guerard, N

Garweg, JG

Document Type

Article

Year published

2022

Published

in AMERICAN JOURNAL OF OPHTHALMOLOGY, ISSN: 0002-9394

Volume: 238, Pages: 157-172 (16)

Indexing

Wos^®

Scopus^®

Pubmed^®

Google Scholar^®

Metadata
Sources

Publication Identifiers

DOI: 10.1016/j.ajo.2022.01.004

Pubmed: 35038415

SCOPUS: 2-s2.0-85127880524

Wos: WOS:000805763900018

Source Identifiers

ISSN: 0002-9394

Export Publication Metadata

Marked List

Add to Marked List

Info

At this moment we don't have any links to full text documens.

Kestrel and Kite: 52-Week Results From Two Phase Iii Pivotal Trials of Brolucizumab for Diabetic Macular Edema

Useful Links

Get Help

Federated Authentication (Click on the image)

Kestrel and Kite: 52-Week Results From Two Phase Iii Pivotal Trials of Brolucizumab for Diabetic Macular Edema

Useful Links

Get Help